AMMJ · American Cannabis Company, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $431.9K | $255.7K | - | $599.9K | $852.7K | $712.4K | - | $2.12M | $4.74M | $619.8K |
| Cost of Revenue | $735.0K | $150.0K | - | - | $486.3K | $435.9K | - | $1.86M | $4.10M | $452.3K |
| Gross Profit | ($303.1K) | $105.7K | - | $248.7K | $366.4K | $276.5K | - | $259.2K | $640.6K | $167.5K |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $249.3K | $232.1K | - | $326.4K | $438.0K | $643.6K | - | $617.3K | $741.4K | $592.3K |
| Total Operating Expenses | $253.6K | $234.5K | - | $378.1K | $498.8K | $717.2K | - | $737.5K | $824.1K | $676.5K |
| D&A | - | $71.6K | - | - | - | $61.3K | - | - | - | $37.5K |
| Operating Income | ($556.7K) | ($128.8K) | - | ($129.4K) | ($132.4K) | ($440.7K) | - | ($478.3K) | ($183.5K) | ($233.2K) |
| Interest Expense | $32.7K | $7.5K | - | - | - | - | - | - | $18.2K | $27.1K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($636.2K) | ($132.6K) | - | ($157.2K) | $11.8K | ($463.0K) | - | ($397.6K) | ($170.8K) | ($522.2K) |
| EPS - Basic | $0.00 | $0.00 | - | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | ($0.01) |
| EPS - Diluted | $0.00 | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.7K | $10.0K | $21.1K | $8.9K | $92.7K | $56.5K | $117.5K | $191.5K | $873.8K | $4.32M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $265.8K | $669.9K | $586.2K | $518.3K | $508.3K | $373.7K | $353.0K | $352.5K | $280.2K | $317.2K |
| Accounts Payable | $1.18M | $1.07M | $1.01M | $935.0K | $809.3K | $793.8K | $679.2K | $453.7K | $509.7K | $393.6K |
| Current Assets | $419.1K | $817.6K | $900.4K | $803.3K | $981.9K | $860.8K | $1.02M | $943.2K | $1.47M | $6.33M |
| Total Assets | $2.12M | $2.63M | $2.83M | $4.17M | $4.45M | $4.41M | $4.62M | $4.28M | $4.81M | $9.47M |
| Current Liabilities | $2.20M | $2.15M | $2.17M | $2.07M | $2.17M | $2.19M | $2.10M | $2.92M | $3.06M | $7.07M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $2.76M | $2.76M | $2.83M | $2.80M | $2.96M | $2.93M | $2.75M | $3.02M | $3.15M | $7.74M |
| Stockholders' Equity | ($636.0K) | ($131.0K) | $1.6K | $1.32M | $1.49M | $1.48M | $1.87M | $1.26M | $1.65M | $1.74M |
| Retained Earnings | ($14.51M) | ($13.87M) | ($13.74M) | ($10.66M) | ($10.53M) | ($10.54M) | ($10.08M) | ($10.54M) | ($10.14M) | ($9.97M) |
Cash Flow
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($11.3K) | - | - | - | ($208.6K) | - | - | - | $3.56M |
| Investing Cash Flow | - | - | - | - | - | ($39.1K) | - | - | - | ($8.2K) |
| Financing Cash Flow | - | $249 | - | - | - | $186.6K | - | - | - | $92.5K |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | -70.2% | 41.3% | - | 41.5% | 43.0% | 38.8% | - | 12.2% | 13.5% | 27.0% |
| Operating margin | -128.9% | -50.4% | - | -21.6% | -15.5% | -61.9% | - | -22.5% | -3.9% | -37.6% |
| EBITDA margin | - | -22.4% | - | - | - | -53.3% | - | - | - | -31.6% |
| Net margin | -147.3% | -51.8% | - | -26.2% | 1.4% | -65.0% | - | -18.7% | -3.6% | -84.2% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 57.7% | 90.8% | - | 54.4% | 51.4% | 90.3% | - | 29.1% | 15.6% | 95.6% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -30.0% | -5.0% | - | -3.8% | 0.3% | -10.5% | - | -9.3% | -3.6% | -5.5% |
| Return on equity | 100.0% | 101.2% | - | -11.9% | 0.8% | -31.3% | - | -31.6% | -10.3% | -30.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.19 | 0.38 | 0.42 | 0.39 | 0.45 | 0.39 | 0.49 | 0.32 | 0.48 | 0.90 |
| Quick ratio | 0.07 | 0.07 | 0.14 | 0.14 | 0.22 | 0.22 | 0.32 | 0.20 | 0.39 | 0.85 |
| Cash ratio | 0.00 | 0.00 | 0.01 | 0.00 | 0.04 | 0.03 | 0.06 | 0.07 | 0.29 | 0.61 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -17.0x | -17.2x | - | - | - | - | - | - | -10.1x | -8.6x |
| Equity multiplier | -3.34 | -20.06 | 1825.21 | 3.15 | 2.98 | 2.98 | 2.47 | 3.40 | 2.91 | 5.46 |
| Liabilities / Assets | 1.30 | 1.05 | 1.00 | 0.67 | 0.66 | 0.66 | 0.59 | 0.71 | 0.66 | 0.82 |
| Efficiency | ||||||||||
| Asset turnover | 0.20 | 0.10 | - | 0.14 | 0.19 | 0.16 | - | 0.50 | 0.99 | 0.07 |
| Inventory turnover | 2.77 | 0.22 | - | - | 0.96 | 1.17 | - | 5.29 | 14.64 | 1.43 |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 132d | 1630d | - | - | 381d | 313d | - | 69d | 25d | 256d |
| Days payable outstanding | 586d | 2604d | - | - | 607d | 665d | - | 89d | 45d | 318d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 2.8x | 4.9x | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -49.4% | -64.1% | - | -71.8% | -82.0% | 14.9% | - | 182.0% | 665.2% | 90.1% |
| Revenue CAGR (3y) | -11.4% | -7.8% | - | 30.7% | 15.7% | 17.4% | - | 43.1% | 86.5% | 14.7% |
| Revenue CAGR (5y) | -10.0% | -9.0% | - | 13.8% | 36.8% | 20.6% | - | 16.5% | 37.9% | 0.1% |
| Gross profit growth (YoY) | - | -61.8% | - | -4.0% | -42.8% | 65.0% | - | -21.2% | 147.6% | -9.0% |
| Operating income growth (YoY) | -320.5% | 70.8% | - | 73.0% | 27.8% | -89.0% | - | -83.0% | -63.3% | - |
| Net income growth (YoY) | - | 71.4% | - | 60.5% | - | 11.3% | - | -151.2% | 53.7% | -328.4% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -99.9% | 5.3% | -9.8% | -14.7% | -11.8% | -54.8% | -43.1% | -30.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Business segments
$756.9K totalAll Other Segments$756.9K · 100.0%
Peer comparison
Same SIC group: Medicinal Chemicals & Botanical Products
Comparing American Cannabis Company against the 5 most active filers in the same SIC group.